Key result
Monte Carlo simulations suggest that a delayed rivaroxaban dose should be taken immediately if delayed ≤6 hours, a half dose if delayed 6-20 hours, and skipped if delayed >20 hours.
Why the study?
Delayed or missed doses of rivaroxaban are common during long-term therapy in patients with non-valvular atrial fibrillation, requiring appropriate remedial dosing regimens.
Does a model-informed remedial dosing regimen reduce deviation time outside the on-therapy range compared to EHRA guidelines in patients with NVAF with delayed or missed rivaroxaban doses?
Does a model-informed remedial dosing regimen reduce deviation time outside the on-therapy range compared to EHRA guidelines in patients with NVAF with delayed or missed rivaroxaban doses?
Answers are grounded in this paper and cite their sources.
Model-informed remedial dosing for delayed rivaroxaban provides a more individualized strategy that minimizes deviation from therapeutic ranges compared to current EHRA guidelines.
BACKGROUND: Rivaroxaban is an oral anticoagulant widely used for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). During long-term anticoagulant therapy, delayed or missed doses are common. This study aimed to explore appropriate remedial dosing regimens for non-adherent rivaroxaban-treated patients. METHODS: Monte Carlo simulation based on a previously established rivaroxaban population pharmacokinetic/pharmacodynamic (PK/PD) model for patients with NVAF was employed to design remedial dosing regimens. The proposed regimens were compared with remedial strategies in the European Heart Rhythm Association (EHRA) guide by assessing deviation time in terms of drug concentration, factor Xa activity, and prothrombin time. RESULTS: The proposed remedial dosing regimens were dependent on delay duration. The missed dose should be taken immediately when the delay does not exceed 6 h; a half dose is advisable when the delay is between 6 and 20 h. A missed dose should be skipped if less than 4 h remains before the next dose. The proposed regimens resulted in shorter deviation time than that of the EHRA guide. CONCLUSION: PK/PD modeling and simulation provide valid evidence on the remedial dosing regimen of rivaroxaban, which could help to minimize the risk of bleeding and thromboembolism.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) studied Non-valvular atrial fibrillation (n=5,000). Remedial dosing strategies for delayed or missed rivaroxaban vs. EHRA recommendations was evaluated on Deviation time (duration when simulated rivaroxaban concentration, FXa activity, or PT are outside the on-therapy range). Monte Carlo simulations suggest that a delayed rivaroxaban dose should be taken immediately if delayed ≤6 hours, a half dose if delayed 6-20 hours, and skipped if delayed >20 hours.
Synapse has enriched 10 related papers. Consider them for comparative context: